Anixa Biosciences
Anixa Biosciences
ANIX
NASDAQ
2.89
USD
2.85%
About
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer.
Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer.
The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 57.3K |
| Three Month Average Volume | 2.1M |
| High Low | |
| Fifty-Two Week High | 5.13 USD |
| Fifty-Two Week Low | 2.145 USD |
| Fifty-Two Week High Date | 18 Jan 2024 |
| Fifty-Two Week Low Date | 28 Jun 2024 |
| Price and Volume | |
| Current Price | 3.34 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.20% |
| Thirteen Week Relative Price Change | 28.42% |
| Twenty-Six Week Relative Price Change | -13.46% |
| Fifty-Two Week Relative Price Change | -27.37% |
| Year-to-Date Relative Price Change | -27.31% |
| Price Change | |
| One Day Price Change | 0.60% |
| Thirteen Week Price Change | 37.45% |
| Twenty-Six Week Price Change | -4.84% |
| Five Day Price Change | 5.03% |
| Fifty-Two Week Price Change | -8.99% |
| Year-to-Date Price Change | -13.92% |
| Month-to-Date Price Change | 0.60% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.7814 USD |
| Book Value Per Share (Most Recent Quarter) | 0.73807 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.7814 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.73807 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.41365 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00678 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.31669 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.36944 USD |
| Normalized (Last Fiscal Year) | -0.31149 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.31669 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.36944 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.31669 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.36944 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.76557 USD |
| Cash Per Share (Most Recent Quarter) | 0.72607 USD |
| Cash Flow Per Share (Last Fiscal Year) | -99999.99 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.22894 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,956 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -4,728.57% |
| Pretax Margin (5 Year) | -6,040.10% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -5,243.33% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -6,158.34% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -4,728.57% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -6,040.10% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 22.14% |
| Tangible Book Value (5 Year) | 39.56% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | -28.36% |
| Revenue Change (Trailing Twelve Months) | -100.00% |
| Revenue Per Share Growth | -36.00% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -32.97% |
| EPS Change (Trailing Twelve Months) | -4.89% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 4 |
| Price to Tangible Book (Most Recent Quarter) | 5 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -23,239,000 |
| Net Debt (Last Fiscal Year) | -23,844,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 509 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 13 |
| Current Ratio (Most Recent Quarter) | 14 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -6,209,000 |
| Free Cash Flow (Trailing Twelve Months) | -7,179,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -35.51% |
| Return on Assets (Trailing Twelve Months) | -45.19% |
| Return on Assets (5 Year) | -59.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -36.76% |
| Return on Equity (Trailing Twelve Months) | -45.98% |
| Return on Equity (5 Year) | -62.15% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -37.00% |
| Return on Investment (Trailing Twelve Months) | -46.33% |
| Return on Investment (5 Year) | -62.61% |